Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587740 · ClinicalTrials.gov registry record · Phase 2
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 14
- Study locations
NCT03587740 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 82 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 14 study locations across 9 states.
The verdict
NCT03587740, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 14
- Study locations
Study Summary
This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer. The drug involved in this study is: -ado-trastuzumab emtansine (T-DM1)
Conditions Studied
Interventions
- DRUG T-DM1
Study Locations (14)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center - Brighton
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center - Milford
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital - South Weymouth
North Carolina
- University of North Carolina - Chapel Hill
- Rex Cancer Center - Raleigh
California
- City of Hope Comprehensive Cancer Center - Duarte
Connecticut
- The Stamford Hospital - Stamford
Minnesota
- Mayo Clinic - Rochester
New Hampshire
- Dana-Farber/New Hampshire Oncology-Hematology - Londonderry
New York
- Memorial Sloan Kettering Cancer Center - New York
Rhode Island
- Lifespan Cancer Institute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2018-08-22 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03587740
The ClinicalTrials.gov registry entry for NCT03587740 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which T-DM1 is the first listed.
NCT03587740 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT03587740 about?
NCT03587740 is a clinical study titled "ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer". This research study is studying an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer. The drug involved in this study is: -ado-trastuzumab emtansine (T-DM1)
What is the current status of trial NCT03587740?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2018-08-22. Estimated completion is 2027-08-30.
What conditions does trial NCT03587740 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03587740?
The interventions under investigation include: T-DM1 (DRUG).
Who is sponsoring clinical trial NCT03587740?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03587740 being conducted?
This trial has 14 study locations across California, Connecticut, Massachusetts, Minnesota, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.